Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2024-11-14 8:21 pm Purchase | 2024-11-08 | 13G | Perspective Therapeutics, Inc. CATX | Farallon Capital Partners L.P. | 5,064,227 7.300% | 5,064,227 (New Position) | Filing History |
2024-11-08 5:15 pm Purchase | 2024-09-30 | 13G | Longboard Pharmaceuticals, Inc. LBPH | Farallon Capital Partners L.P. | 3,456,063 9.990% | 1,250,073 (+56.67%) | Filing History |
2024-11-08 2:57 pm Sale | 2024-09-30 | 13G | Aramark ARMK | Farallon Capital Partners L.P. | 11,636,937 4.400% | -5,262,317 (-31.14%) | Filing History |
2024-11-08 2:40 pm Purchase | 2024-09-30 | 13G | Agios Pharmaceuticals, Inc. AGIO | Farallon Capital Partners L.P. | 5,660,866 9.900% | 1,493,264 (+35.83%) | Filing History |
2024-11-08 11:54 am Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Farallon Capital Partners L.P. | 3,527,482 6.000% | 427,482 (+13.79%) | Filing History |
2024-11-07 09:56 am Purchase | 2024-09-30 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 8,208,123 9.900% | 4,102,370 (+99.92%) | Filing History |
2024-11-06 6:32 pm Purchase | 2024-09-30 | 13G | Savara Inc. SVRA | Farallon Capital Partners L.P. | 17,762,533 9.990% | 3,435,622 (+23.98%) | Filing History |
2024-11-06 5:06 pm Sale | 2024-09-30 | 13G | Swiftmerge Acquisition Corp. IVCP | Farallon Capital Partners L.P. | 471,366 9.900% | -53,634 (-10.22%) | Filing History |
2024-10-16 4:35 pm Purchase | 2024-10-09 | 13D | Squarespace, Inc. SQSP | Farallon Capital Partners L.P. | 5,600,000 6.100% | 5,600,000 (New Position) | Filing History |
2024-05-17 4:58 pm Purchase | 2024-05-09 | 13G | NanoString Technologies, Inc. NSTGQ | Farallon Capital Partners L.P. | 4,391,941 9.100% | 4,391,941 (New Position) | Filing History |
2024-05-08 4:11 pm Purchase | 2024-05-06 | 13D | Exelixis, Inc. EXEL | Farallon Capital Partners L.P. | 26,769,500 9.200% | 909,500 (+3.52%) | Filing History |
2024-02-14 09:33 am Purchase | 2023-12-31 | 13G | Forte Biosciences, Inc. FBRX | Farallon Capital Partners L.P. | 151,740 9.900% | 234 (+0.15%) | Filing History |
2024-02-12 5:11 pm Sale | 2023-12-31 | 13G | Revolution Medicines, Inc. RVMD | Farallon Capital Partners L.P. | 6,750,204 4.100% | -12,276 (-0.18%) | Filing History |
2024-02-12 3:38 pm Sale | 2023-12-31 | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 4,105,753 5.000% | -7,716 (-0.19%) | Filing History |
2024-02-08 11:39 am Purchase | 2023-12-31 | 13G | Agios Pharmaceuticals, Inc. AGIO | Farallon Capital Partners L.P. | 4,167,602 7.500% | 206,000 (+5.20%) | Filing History |
2024-02-06 10:16 am Purchase | 2023-12-31 | 13G | Aramark ARMK | Farallon Capital Partners L.P. | 16,899,254 6.400% | 1,518,185 (+9.87%) | Filing History |
2024-02-05 5:28 pm Unchanged | 2024-02-01 | 13D | Cazoo Group Ltd CZOOF | Farallon Capital Partners L.P. | 7,142 14.600% | 0 (Unchanged) | Filing History |
2024-02-05 11:22 am Sale | 2023-12-31 | 13G | Swiftmerge Acquisition Corp. IVCP | Farallon Capital Partners L.P. | 525,000 9.000% | -1,680,000 (-76.19%) | Filing History |
2024-02-02 09:19 am Purchase | 2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | Farallon Capital Partners L.P. | 5,765,109 9.990% | 710,007 (+14.05%) | Filing History |
2024-02-01 3:50 pm Purchase | 2023-12-31 | 13G | Savara Inc. SVRA | Farallon Capital Partners L.P. | 14,326,911 9.990% | 14,326,911 (New Position) | Filing History |